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Abstract
Introduction Patients undergoing elective total hip or total
knee replacement surgery are at increased risk of venous
thromboembolism in the post-operative period and are
recommended to receive thromboprophylaxis for 10–
35 days. Although several thromboprophylactic agents are
available, these are associated with well-recognized limi-
tations. For the low molecular weight heparins (LMWHs)
such as enoxaparin, these limitations include parenteral
administration, indirect mode of action, inability to inhibit
clot-bound thrombin and association with complications
such as heparin-induced thrombocytopenia. These limita-
tions make post-operative thromboprophylaxis challenging.
Several new oral anticoagulants are in the advanced stages
of clinical development. These agents have been designed
to target either thrombin (dabigatran etexilate) or factor Xa
(rivaroxaban and apixaban), which are key coagulation
cascade enzymes.
Methods and results This review will present the published
phase III clinical trial evidence of the efficacy and safety of
dabigatran etexilate, rivaroxaban and apixaban, compared
with the LMWH enoxaparin for the prevention of venous
thromboembolism in patients who have undergone elective
total hip or total knee replacement surgery. All three agents
have shown comparable or superior efficacy compared with
the European dose regimen of enoxaparin (40 mg once
daily), and comparable rates of major bleeding events.
Dabigatran etexilate and rivaroxaban are currently licensed
for use following elective hip and knee replacement surgery
in many countries, but no direct comparative data exist
upon which to base the choice of agent.
Conclusion A thorough assessment of each individual
patient’s thromboembolic and bleeding risks should be the
basis of selecting the agent in order to balance efficacy and
safety.
Keywords Apixaban.Dabigatran etexilate.Oral
anticoagulants.Orthopaedics.Rivaroxaban.Venous
thromboembolism
Introduction
Orthopaedic surgery, such as total hip and total knee
replacement surgery, is associated with an increased risk of
life-threatening and morbidity-associated venous thrombo-
embolism (VTE) during the peri- and post-operative periods.
As a result, current evidence-based clinical guidelines
recommend the administration of anticoagulants to patients
undergoing orthopaedic surgery [1]. In particular, patients
undergoing elective hip or knee arthroplasty are recommen-
ded to receive thromboprophylaxis for at least 10 days, with
treatment being continued for up to 35 days [1].
Limitations of the current anticoagulants used in hip
and knee arthroplasty
It is extremely important that patients continue to receive
their thromboprophylactic treatment once they have been
discharged from hospital; this can be a challenge because
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in Europe (e.g. the low molecular weight heparins, LMWHs,
such as enoxaparin), are parenterally administered. Other
limitations associated with LMWHs, such as their indirect
mode of action, inability to inhibit clot-bound thrombin, and
association with complications such as heparin-induced throm-
bocytopenia and osteoporosis, can have a negative impact on
their long-term, post-operative use [2]. In addition, the oral
vitamin K antagonists (VKAs) such as warfarin, which are
widely used in North America in this setting, are associated
with a number of limitations (e.g. slow onset and offset of
action, narrow therapeutic window, multiple drug and food
interactions, and an unpredictable anticoagulant effect requir-
ing regular anticoagulant monitoring and dose adjustment)
that make their long-term use very problematic.
New oral anticoagulants
There has been a clear need for novel oral anticoagulant
agents for some time, and a number are being developed
that target either one of two specific molecules within the
coagulation cascade, thrombin and factor Xa [3]. Four
agents are at the more advanced stages of clinical
development. Dabigatran etexilate is a direct thrombin
inhibitor that reversibly inhibits the active site of thrombin,
which is a central player in the coagulation cascade
converting fibrinogen to fibrin. Rivaroxaban, apixaban
and edoxaban are all factor Xa inhibitors, which bind
reversibly to the active site of factor Xa. Table 1 presents
the pharmacokinetic profiles of these four novel anti-
coagulants [3]. The bioavailability of dabigatran etexilate
is much lower than that of the other three agents, so a
higher dose of this agent is required. All four agents are
given as a fixed dose, and their anticoagulant effects are so
predictable that they do not require routine coagulation
monitoring. In total knee or hip replacement, dabigatran
etexilate, rivaroxaban and edoxaban are all administered
once daily, while apixaban is administered twice daily.
Dabigatran etexilate is mainly cleared by the kidneys, so
care must be exercised in patients with renal insufficiency
(creatinine clearance, 30–50 ml/min) [4]. Compared with
the VKAs, there are few drug interactions with these novel
oral anticoagulants, although they do interact with (i) potent
inhibitors of P-glycoprotein (all except apixaban) and (ii)
potent inhibitors of the cytochrome P450 enzyme CYP3A4
(all except dabigatran etexilate) [3].
Evidence of primary VTE prevention from clinical trials
The remainder of this review will focus on the published
evidence from the clinical trial programmes for dabigatran
etexilate, rivaroxaban and apixaban, in terms of the
evaluation of their efficacy and safety for the primary
prevention of VTE in patients undergoing elective hip and
knee replacement surgery.
Dabigatran etexilate
Three phase III clinical trials that form part of the RE-
VOLUTION® study programme undertaken by Boehringer
Ingelheim have been completed and published on the
efficacy and safety of dabigatran etexilate for the primary
prevention of VTE following elective hip and knee
replacement surgery [5–7]. The three clinical trials had
identical non-inferiority study designs with a primary
endpoint of a composite of total VTE (asymptomatic and
symptomatic deep vein thromboses and non-fatal pulmo-
nary embolism) and all-cause death during treatment. The
Table 1 Pharmacokinetic profiles of the new oral anticoagulant agents [3]
Characteristic Dabigatran etexilate Rivaroxaban Apixaban Edoxaban
Target Thrombin Factor Xa Factor Xa Factor Xa
Prodrug Yes No No No
Bioavailability (%) 6 80 60 50
Dosing Once daily Once daily Twice daily Once daily
Half-life (h) 12–17 7–11 12 9–11
Renal clearance (%) 80 66 25 35
Routine coagulation monitoring No No No No
Drug interactions
a Potent inhibitors
of P-glycoprotein
Potent inhibitors of CYP3A4
and P-glycoprotein
Potent inhibitors
of CYP3A4
Potent inhibitors of CYP3A4
and P-glycoprotein
Adapted from [3]
aPotent inhibitors of P-glycoprotein include quinidine. Weak inhibitors of P-glycoprotein include amiodarone. Potent inhibitors of CYP3A4
include azole anti-fungals, macrolide antibiotics and protease inhibitors. Potent inhibitors of both P-glycoprotein and CYP3A4 include azole anti-
fungals and protease inhibitors
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during treatment. Major bleeding during the treatment
period was defined as: clinically overt bleeding associated
with ≥20 g/l fall in haemoglobin; clinically overt bleeding
leading to a transfusion of ≥2 units of packed cells or whole
blood; fatal, retroperitoneal, intracranial, intraocular or
intraspinal bleeding and bleeding warranting treatment
cessation or leading to reoperation. The definition of major
bleeding was consistent with the Committee for Proprietary
Medicinal Products [8]. It is important to note that the
assessment of bleeding also included surgical site bleeds.
All efficacy and safety outcomes were assessed by an
independent, central adjudication committee.
The RE-NOVATE® I trial randomized 3,494 patients
undergoing total hip replacement surgery to receive 28–
35 days of either dabigatran etexilate, 220 mg (n=1,157) or
150 mg (n=1,174) once daily, or subcutaneous enoxaparin,
40 mg (n=1,162) once daily [5]. The dose of enoxaparin
was equivalent to that used routinely in the European Union
(EU). The RE-MODEL™ trial randomized 2,101 patients
undergoing total knee replacement surgery to receive 6–
10 days of either dabigatran etexilate, 220 mg (n=694) or
150 mg (n=708) once daily, or subcutaneous enoxaparin,
40 mg (n=699) once daily [6]. The third trial, RE-
MOBILIZE®, used the North American enoxaparin regimen
of 30 mg enoxaparin (n=876) twice daily, compared with
either dabigatran etexilate, 220 mg (n= 8 6 2 )o r1 5 0m g( n=
877) once daily for 12–15 days, in patients undergoing total
knee replacement surgery [7]. The follow-up period for these
trials was 12–14 weeks.
In both the RE-NOVATE® I and RE-MODEL™ trials,
dabigatran etexilate demonstrated non-inferiority with the
EU dose of enoxaparin (40 mg once daily) for the primary
efficacy composite outcome of total VTE and all-cause
mortality (Fig. 1)[ 5, 6]. In RE-NOVATE® I, 6.7% (60/897)
of the enoxaparin group, compared with 6.0% (53/880) of
the dabigatran etexilate 220-mg group and 8.6% (75/874)
of the dabigatran etexilate 150-mg group, experienced a
primary efficacy outcome event (Fig. 1a)[ 5]. Although the
rates of the primary efficacy outcome were higher in the
RE-MODEL™ trial, as expected for knee replacement
surgery, there were no significant differences between the
three groups: 37.7% (193/512) of the enoxaparin group
compared with 36.4% (183/503) of the dabigatran etexilate
220-mg group and 40.5% (213/526) of the dabigatran
etexilate 150-mg group (Fig. 1b)[ 6].
In terms of safety, both the RE-NOVATE® I and RE-
MODEL™ trials demonstrated similar major bleeding rates
for the two dabigatran etexilate groups and the enoxaparin
group (Fig. 2)[ 5, 6]. In RE-NOVATE® I, major bleeding
occurred in 1.6% of the enoxaparin group, compared with
2.0% of the dabigatran etexilate 220-mg group and 1.3% of
the dabigatran etexilate 150-mg group (Fig. 2a)[ 5].
Similarly, in RE-MODEL™, major bleeding events
occurred in 1.3% of the enoxaparin group, compared
with 1.5% of the dabigatran etexilate 220-mg group and
1.3% of the dabigatran etexilate 150-mg group (Fig. 2b)[ 6].
In the RE-MOBILIZE® trial, when dabigatran etexilate
(220 mg and 150 mg once daily) was compared with the
North American dose of enoxaparin (30 mg twice daily), it
was associated withnumerically fewer major bleeding events,
while it did not statistically achieve non-inferior efficacy,
likely due to the 50% higher US dose of enoxaparin used in
the study and the prolonged dosing regimen [7].
In summary, the three clinical trials described above
demonstrated that dabigatran etexilate was as effective as
the EU dose of enoxaparin (40 mg once daily) at preventing
VTE and all-cause mortality after total hip or total knee
replacement surgery, but less effective than the North
American dose of enoxaparin (30 mg twice daily) following
knee arthroplasty. The safety profile of dabigatran etexilate
was comparable with that of enoxaparin after either total
hip or total knee replacement surgery. There were no
significant differences between dabigatran etexilate and
enoxaparin in terms of bleeding outcomes, the incidence of
liver enzyme elevations (of particular relevance because of
the problems experienced with another direct thrombin
inhibitor, ximelagatran), and the incidence of acute coro-
nary events either on or off therapy, which suggests there is
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Fig. 1 Composite of total venous thromboembolic events (asymp-
tomatic deep vein thrombosis and non-fatal pulmonary embolism)
and all-cause mortality during treatment with either dabigatran
etexilate, 150 mg or 220 mg once daily, or enoxaparin, 40 mg once
daily: 28–35 days in RE-NOVATE® I (n=3,494) (a)a n d6 –10 days
in RE-MODEL™ (n=2,076) (b)t r i a l s[ 5, 6]
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[5–7]. A fourth, phase III clinical trial of dabigatran etexilate
for the primary prevention of VTE following elective hip
replacement surgery, RE-NOVATE® II (RE-NOVATE® II;
ClinicalTrials.gov identifier: NCT00657150) [9], has recently
been completed, and the results were reported at the 15th
Congress of the European Hematology Association held in
June 2010. In this double-blind, non-inferiority trial, patients
(n=2,055) undergoing total hip arthroplasty were randomized
to receive either oral dabigatran etexilate, 220 mg once daily,
or subcutaneous enoxaparin, 40 mg once daily, for 28–
35 days [9]. Dabigatran etexilate demonstrated non-inferiority
to enoxaparin for the primary efficacy outcome, a composite
of total VTE and all-cause mortality, which occurred in 7.7%
(61/792) of the dabigatran etexilate group versus 8.8%
(69/785) of the enoxaparin group [9]. Major bleeding
rates were comparable in both groups and occurred in
1.4% of the dabigatran etexilate group and 0.9% of the
enoxaparin group. Adverse events did not differ signifi-
cantly between the two groups [9]. The study concluded
that oral dabigatran etexilate, 220 mg once daily, was as
effective as subcutaneous enoxaparin, 40 mg once daily, in
reducing the VTE risk after total hip arthroplasty, with
similar safety profiles and bleeding risk [9].
Rivaroxaban
As part of the RECORD clinical programme being
undertaken by Bayer Schering Pharma AG, four phase III
clinical trials have been completed and published on the
efficacy and safety of rivaroxaban for the primary preven-
tion of VTE following hip and knee arthroplasty [10–14]
(Table 2). Of particular note is that the incidence of surgical
site bleeding was not included in the bleeding data for the
RECORD trials, which resulted in lower overall rates of
bleeding compared with clinical trials of other thrombopro-
phylactic agents such as dabigatran etexilate [5, 6].
The RECORD1 trial randomized 4,541 patients under-
going total hip replacement surgery to receive either
rivaroxaban, 10 mg (n=2,266) once daily, or subcutaneous
enoxaparin, 40 mg (n=2,275) once daily, for 35 days [10].
Significantly fewer patients in the rivaroxaban group
(1.1%; 18/1,595) experienced a primary efficacy outcome
event of deep vein thrombosis (symptomatic or
venography-confirmed asymptomatic), non-fatal pulmonary
embolism or death from any cause at 36 days, compared
with patients in the enoxaparin group (3.7%; 58/1,558)
(Table 2)[ 10]. There was no significant difference between
the two groups in the rate of major bleeding (0.3% for
rivaroxaban versus 0.1% for enoxaparin) (Fig. 3)[ 10].
Similarly, the RECORD2 trial that was also undertaken
in hip replacement patients (n=2,509) demonstrated supe-
rior efficacy for rivaroxaban compared with enoxaparin for
the same primary outcome composite, although it should be
noted that rivaroxaban was administered for a longer period
of time than enoxaparin (31–39 days versus 10–14 days,
respectively) (Table 2)[ 11]. The major bleeding rates were
identical for the two groups (0.08%) (Fig. 3)[ 11].
Two studies, RECORD3 [12] and RECORD4 [13], were
undertaken in patients undergoing total knee replacement
surgery. RECORD3 randomized 2,531 patients to receive
either rivaroxaban, 10 mg (n=1,254) once daily, or subcuta-
neous enoxaparin, 40 mg (n=1,277) once daily, for 10–
14 days [12]. In contrast, RECORD4 compared rivaroxaban,
10 mg (n=1,584) once daily, with the North American dose
of enoxaparin (30 mg twice daily; n=1,564) [13]. Both
studies demonstrated significantly fewer primary outcome
events (VTE events and all-cause mortality) with rivaroxaban
compared with enoxaparin (Table 2) and comparable rates of
major bleeding (RECORD3: 0.6% versus 0.5%, respectively;
RECORD4: 0.7% versus 0.3%, respectively) (Fig. 3)[ 12, 13].
In summary, once daily oral rivaroxaban (10 mg) was
significantly more effective than subcutaneous enoxaparin
(both the EU and North American doses) at preventing
VTE-related events after either elective hip or knee
replacement surgery. There was no significant increase in
the rate of major bleeding between rivaroxaban and
enoxaparin, but surgical site bleeds were not included in
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Fig. 2 Major bleeding events during treatment with either dabigatran
etexilate, 150 mg or 220 mg once daily, or enoxaparin, 40 mg once
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10 Eur Orthop Traumatol (2011) 2:7–14the safety outcome evaluation, and it is known from other
studies that these contribute considerably to the total major
bleeding rate [5, 6]. Bleeding into the surgical site is of
clinical importance to orthopaedic surgeons because of the
negative impact it can have on the risk of wound infection
and the need for reoperation of the prosthetic joint.
Apixaban
The ADVANCE clinical programme, which is being
coordinated by Bristol–Myers Squibb and Pfizer, is
evaluating the thromboprophylactic efficacy and safety of
apixaban in a range of indications. Two phase III clinical
trials that have been undertaken in orthopaedic patients
have been published to date: the ADVANCE-1 and
ADVANCE-2 studies in patients undergoing total knee
replacement [15, 16]. Similar to the dabigatran etexilate
trials, these studies included bleeding at the surgical site in
their safety analyses. The ADVANCE-1 study compared
10–14 days of treatment with apixaban (2.5 mg twice daily)
with enoxaparin at the North American dose (30 mg twice
daily) in 3,195 patients, and failed to show non-inferiority
for apixaban for the composite primary efficacy outcome of
total VTE events and all-cause mortality (Fig. 4a)[ 15]. This
Table 2 The main efficacy outcomes of the four RECORD trials in patients undergoing elective hip or knee arthroplasty [10–14]
Trial Setting Enoxaparin subcutaneous Rivaroxaban oral Deep vein thrombosis/pulmonary embolism/death
Events (%) Relative risk reduction (%) p value
RECORD1,
n=4,541
Total hip arthroplasty 40 mg once daily
for 35 days
10 mg once daily
for 35 days
3.7 versus 1.1 70 <0.001
RECORD2,
n=2,509
Total hip arthroplasty 40 mg once daily
for 10–14 days
10 mg once daily
for 31–39 days
9.3 versus 2.0 79 <0.0001
RECORD3,
n=2,531
Total knee arthroplasty 40 mg once daily
for 10–14 days
10 mg once daily
for 10–14 days
18.9 versus 9.6 49 <0.001
RECORD4,
n=3,148
Total knee arthroplasty 30 mg twice daily
for 10–14 days
10 mg once daily
for 10–14 days
10.1 versus 6.9 31 0.0160
Adapted from [14] Copyright (2010), with permission from Elsevier
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Fig. 3 Major bleeding events during treatment with either rivarox-
aban, 10 mg once daily, or enoxaparin, 40 mg once daily, for 35 days
in RECORD1 during total hip arthroplasty (n=4,541); with either
rivaroxaban, 10 mg once daily for 31–39 days, or enoxaparin, 40 mg
once daily for 10–14 days, in RECORD2 during total hip arthroplasty
(n=2,509); with either rivaroxaban, 10 mg once daily, or enoxaparin,
40 mg once daily, for 10–14 days in RECORD3 during total knee
arthroplasty (n=2,531) and with either rivaroxaban, 10 mg once daily,
or enoxaparin, 30 mg twice daily, for 10–14 days in RECORD4
during total knee arthroplasty (n=3,148). Major bleeding during the
treatment period was defined as bleeding that was fatal, occurred in a
critical organ (e.g. retroperitoneal, intracranial, intraocular or intra-
spinal bleeding), required reoperation or extra-surgical site bleeding
that was clinically overt and was associated with a fall in haemoglobin
level of at least 2 g/dl, or that required transfusion of ≥2 units packed
cells or whole blood [10–13]
Eur Orthop Traumatol (2011) 2:7–14 11was because the incidence of the composite primary
efficacy outcome in patients treated with enoxaparin was
only 55% of the predicted rate that was used to establish the
criteria for non-inferiority and to calculate the sample size
[12]. Apixaban treatment was associated with fewer major
bleeding events than enoxaparin (0.7% versus 1.4%,
respectively) (Fig. 5a)[ 15]. In contrast, the subsequent
ADVANCE-2 study in 3,057 patients demonstrated superi-
or efficacy for apixaban (2.5 mg twice daily) compared
with enoxaparin used at the EU dose (40 mg once daily) for
the same primary efficacy composite outcome (15.1%
versus 24.4%, respectively) (Fig. 4b)[ 16]. In addition,
there was no significant difference in the rate of major
bleeding (apixaban, 0.6%; enoxaparin, 0.9%) (Fig. 5b) and
the rate of the composite of major bleeding and clinically
relevant non-major bleeding between the two treatment
groups (apixaban, 3.5%; enoxaparin, 4.8%) [16].
In summary, apixaban demonstrated superiority com-
pared with the EU dose of enoxaparin (40 mg once
daily) but failed to show non-inferiority compared with
the North American dose of enoxaparin (30 mg twice
daily) for the prevention of VTE following total knee
replacement surgery [15, 16]. In terms of the incidence of
major bleeding, apixaban demonstrated rates that were
comparable with both enoxaparin dosing regimens.
Treatment choice
Of the new oral anticoagulants, dabigatran etexilate and
rivaroxaban have been approved for use in patients
following hip and knee replacement surgery in many
countries. No direct head-to-head comparisons of these
two agents have been made. However, a meta-analysis of
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Fig. 5 Major bleeding events during treatment with either apixaban,
2.5 mg twice daily, or enoxaparin, 30 mg twice daily, for 10–14 days
in the ADVANCE-1 study (n=3,195) during total knee arthroplasty
(a); and with either apixaban, 2.5 mg twice daily, or enoxaparin,
40 mg once daily, for 10–14 days in the ADVANCE-2 study (n=
3,057) during total knee arthroplasty (b). Major bleeding was defined
as acute, clinically overt bleeding accompanied by one or more of the
following events: a decrease in the haemoglobin level of 2 g/dl or
more within a 24-h period; a transfusion of ≥2 or more units of packed
red cells; bleeding at a critical site (i.e. intracranial, intraspinal,
intraocular, pericardial or retroperitoneal bleeding); bleeding into the
operated joint, requiring an additional operation or intervention;
intramuscular bleeding with the compartment syndrome or fatal
bleeding [15, 16]
12 Eur Orthop Traumatol (2011) 2:7–14the pivotal studies comparing dabigatran etexilate with
enoxaparin (n=8,185) or rivaroxaban with enoxaparin (n=
10,220) for VTE prevention after total hip and total knee
replacement surgery was undertaken using standardized
bleeding definitions for major, plus clinically relevant non-
major, bleeding [17]. This post hoc analysis demonstrated
that dabigatran etexilate showed similar rates of efficacy
and bleeding compared with enoxaparin (symptomatic VTE
or death, 1.1% versus 0.9%, respectively; major plus
clinically relevant non-major bleeding, 5.6% versus 5.0%,
respectively), while rivaroxaban was more effective than
enoxaparin but had a significantly higher risk of bleeding
(symptomatic VTE or all-cause mortality, 0.6% versus
1.2%, respectively, p<0.001 for the odds ratio; major plus
clinically relevant non-major bleeding, 3.1% versus 2.5%,
respectively, p=0.049 for the odds ratio) [17].
Conclusions
Three new oral anticoagulant agents have been evaluated in
phase III clinical trials for VTE prevention in elective hip
and knee replacement surgery compared with the LMWH
enoxaparin administered subcutaneously, and the results
have been published. Dabigatran etexilate, a direct throm-
bin inhibitor, at doses of 220 or 150 mg once daily, has
been shown to be as effective and safe as the EU dose of
enoxaparin (40 mg once daily) and less effective, but
equally safe, as the North American dose regimen of
enoxaparin (30 mg twice daily). The factor Xa inhibitor
rivaroxaban (10 mg once daily) was more effective than
both the EU and North American doses of enoxaparin
whilst maintaining comparable rates of major bleeding.
However, in a meta-analysis of the pivotal studies compar-
ing rivaroxaban with enoxaparin using standardized bleed-
ing definitions for major, plus clinically relevant non-major,
bleeding, rivaroxaban was associated with significantly
higher rates of major bleeding plus clinically relevant
non-major bleeding than enoxaparin. Apixaban (2.5 mg
twice daily), also a factor Xa inhibitor, demonstrated
superior efficacy and comparable safety compared with
the EU dose of enoxaparin but was not as effective as the
North American dose of enoxaparin. Dabigatran etexilate
and rivaroxaban are currently the only new oral anticoag-
ulant agents that are available for thromboprophylaxis
following elective hip and knee replacement surgery. As
there has been no head-to-head trial of these two agents,
direct comparative data upon which to base clinical
decisions are lacking. However, the choice of which oral
anticoagulant agent to use in these surgical patients must be
based on an assessment of each individual patient’s risk
factors for both VTE and bleeding, so that the chosen
treatment ensures a balance between efficacy and safety.
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